Marietta Wealth Management LLC reduced its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 0.6% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,824 shares of the company’s stock after selling 80 shares during the period. Eli Lilly and Company makes up 1.7% of Marietta Wealth Management LLC’s investment portfolio, making the stock its 16th largest holding. Marietta Wealth Management LLC’s holdings in Eli Lilly and Company were worth $11,361,000 at the end of the most recent quarter.
Several other hedge funds have also bought and sold shares of the business. Lynx Investment Advisory purchased a new position in shares of Eli Lilly and Company during the second quarter valued at approximately $32,000. LGT Financial Advisors LLC bought a new position in Eli Lilly and Company during the 2nd quarter valued at $36,000. Cedar Mountain Advisors LLC boosted its holdings in Eli Lilly and Company by 53.3% during the 3rd quarter. Cedar Mountain Advisors LLC now owns 46 shares of the company’s stock worth $41,000 after acquiring an additional 16 shares during the last quarter. Morton Brown Family Wealth LLC grew its stake in shares of Eli Lilly and Company by 45.5% in the 2nd quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock worth $41,000 after acquiring an additional 15 shares in the last quarter. Finally, Unique Wealth Strategies LLC purchased a new stake in shares of Eli Lilly and Company in the second quarter valued at about $45,000. Institutional investors and hedge funds own 82.53% of the company’s stock.
Eli Lilly and Company Stock Performance
Shares of LLY opened at $902.96 on Thursday. Eli Lilly and Company has a 12-month low of $547.61 and a 12-month high of $972.53. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. The company has a market cap of $858.18 billion, a PE ratio of 132.98, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. The stock has a 50-day moving average price of $921.12 and a 200-day moving average price of $860.74.
Analyst Ratings Changes
A number of equities research analysts have issued reports on the stock. JPMorgan Chase & Co. upped their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th. Berenberg Bank upped their target price on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Guggenheim lifted their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Truist Financial upped their price objective on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research note on Thursday, October 10th. Finally, Bank of America lifted their target price on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $1,002.24.
Read Our Latest Analysis on LLY
Eli Lilly and Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Read More
- Five stocks we like better than Eli Lilly and Company
- What is the FTSE 100 index?
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- What is Put Option Volume?
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- What is the Dow Jones Industrial Average (DJIA)?
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.